Enalapril in children with Alport syndrome
- 1 March 2004
- journal article
- clinical trial
- Published by Springer Nature in Pediatric Nephrology
- Vol. 19 (3) , 271-275
Abstract
Ten pediatric patients with Alport syndrome received enalapril for 5 years. There were nine boys. Eight patients have the X-linked form of the disease and two the autosomal recessive form. The median age at the start of treatment was 10.25 years. Only one patient was hypertensive. The starting dose of enalapril was 0.05 mg/kg; the target dose was 0.5 mg/kg per day. The median dose given effectively was 0.24, 0.37, 0.45, 0.43, and 0.49 mg/kg per day at years of study 1, 2, 3, 4, and 5, respectively. The median urinary protein/creatinine ratio was 1.58 g/g (range 0.49–4.60) before treatment. This decreased to 0.98, 1.09, 1.35, 1.11, and 1.38 g/g after 1, 2, 3, 4, and 5 years, respectively. The median creatinine clearance at baseline was 100 ml/min per 1.73 m2 (range 82–133) and after 5 years 92 ml/min per 1.73 m2 (range 22–115). Three patients did not reach the target dose of enalapril because of orthostatic hypotension. One of them was the only patient to develop chronic renal failure within 5 years. The present study indicates that enalapril reduces urinary protein excretion and preserves glomerular filtration in Alport patients as a group. However, there was individual variation, as in most studies of patients with proteinuric nephropathies given inhibitors of the angiotensin-converting enzyme.Keywords
This publication has 21 references indexed in Scilit:
- The potential for regression of renal scarringCurrent Opinion in Nephrology and Hypertension, 2003
- Enalapril in paediatric patients with Alport syndrome: 2 years' experienceEuropean Journal of Pediatrics, 2000
- Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-upPediatric Nephrology, 1997
- Treatment of X-linked hereditary nephritis in samoyed dogs with angiotensin converting enzyme (ACE) inhibitorJournal of Comparative Pathology, 1997
- Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)1997
- Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.1997
- Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat.Journal of the American Society of Nephrology, 1997
- Molecular genetics of Alport syndromeKidney International, 1993
- Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal diseaseThe Journal of Pediatrics, 1988
- Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.Journal of Clinical Investigation, 1986